Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ERYTECH Pharma S.A. ERYP
$1.05
-$0.15 (-14.65%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
42711371.00000000
-
week52high
1.47
-
week52low
0.30
-
Revenue
0
-
P/E TTM
98
-
Beta
2.24923600
-
EPS
-0.01000000
-
Last Dividend
0.00000000
-
Next Earnings Date
26 апр 2023 г. в 04:00
Описание компании
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cowen & Co. | Outperform | 05 дек 2017 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Why Is Erytech Pharma (ERYP) Stock Up 47% Today?
InvestorPlace
09 мая 2023 г. в 08:11
Erytech Pharma (NASDAQ: ERYP ) stock is on the rise Tuesday after the company provided investors with a business update for Q1! First up is the company's planned merger with Pherecydes.
ERYTECH Pharma S.A. (ERYP) Q3 2022 Earnings Call Transcript
Seeking Alpha
22 ноя 2022 г. в 10:24
ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q3 2022 Earnings Conference Call November 22, 2022 8:30 AM ET Company Participants Gil Beyen - CEO Eric Soyer - CFO and COO Conference Call Participants Boris Peaker - Cowen Operator Good morning, and thank you for standing by.
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why
Zacks Investment Research
05 окт 2022 г. в 13:32
Erytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%
Zacks Investment Research
26 авг 2022 г. в 15:03
After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.
ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2022 Results - Earnings Call Transcript
Seeking Alpha
13 мая 2022 г. в 11:18
ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Gil Beyen – Chief Executive Officer Eric Soyer – Chief Financial and Chief Operating Officer Dr. Iman El-Hariry – Chief Medical Officer Conference Call Participants Boris Peaker – Cowen and Company Jacob Mekhael – Kempen & Co Operator Good day, and thank you for standing by.